ATXI · Avenue Therapeutics Inc

-

Please sign in to comment on ATXI

1 Comment

Admin

4 years, 1 month ago

Avenue Therapeutics, Inc is currently in a long term downtrend where the price is trading 51.0% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Avenue Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 100.0% to $-5 since the same quarter in the previous year.

Finally, its free cash flow grew by 148.3% to $2M since the same quarter in the previous year.

Based on the above factors, Avenue Therapeutics, Inc gets an overall score of 3/5.

ISIN	US05360L3042
Sector	Healthcare
Industry	Biotechnology
Exchange	PINK
CurrencyCode	USD

Market Cap	724K
PE Ratio	None
Beta	-0.02
Target Price	8
Dividend Yield	None

ABOUT

Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

ATXI · Avenue Therapeutics Inc

-

Avenue Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Avenue Therapeutics Inc using a moving average strategy